Clinical research Ethernia Trial Watch. Follow the question a trial is designed to answer—and the milestone it has actually reached.
Registry snapshots are dated. Completion estimates can move; recruitment status is not a result.
Trial category All categories Immune rejuvenation Longevity drugs Reprogramming Senolytics
4 tracked trials
Published result PEARL The published primary result did not establish improvement in visceral fat. A completed study is not proof of a longevity benefit.
Therapy / candidate Rapamycin
Company / institution AgelessRx
Target / mechanism mTOR inhibition
Phase Phase 2
Population Adults aged 50–85; registry enrollment 129
Primary endpoint Change in visceral fat measured by DXA
Registry status Completed
Start date 2020-01-01
Expected / recorded primary completion 2023-12-30 (actual)
Last checked 2026-09-16
Registry last updated 2024-01-24 Started2020-01-01 Primary completion2023-12-30 (actual)
Registry record ↗ Read Ethernia’s evidence →
Published result Senolytics and bone biology The published dasatinib–quercetin comparison concerns bone markers, not systemic rejuvenation. Registry enrollment includes the broader registered programme.
Therapy / candidate Dasatinib + quercetin / fisetin arms
Company / institution Sundeep Khosla, M.D.
Target / mechanism Senescent-cell targeting
Phase Phase 2
Population Postmenopausal women aged 60+; registry enrollment 74
Primary endpoint Change in serum CTX at 20 weeks
Registry status Completed
Start date 2020-06-09
Expected / recorded primary completion 2023-06-06 (actual)
Last checked 2026-09-16
Registry last updated 2024-07-22 Started2020-06-09 Primary completion2023-06-06 (actual)
Registry record ↗ Read Ethernia’s evidence →
First patient dosed — company-reported ER-100 optic neuropathies The June 2026 dosing announcement is a development milestone. The phase 1 study tests safety in optic neuropathies, not whole-body age reversal.
Therapy / candidate ER-100
Company / institution Life Biosciences Inc.
Target / mechanism Partial epigenetic reprogramming
Phase Phase 1
Population Adults aged 40–85 with OAG or NAION; planned enrollment 18
Primary endpoint Treatment-emergent adverse events, dose-limiting toxicities and other safety assessments
Registry status Recruiting
Start date 2026-03-02
Expected / recorded primary completion 2027-05 (estimated)
Last checked 2026-09-16
Registry last updated 2026-05-19 Started2026-03-02 Primary completion2027-05 (estimated)
Registry record ↗ Read Ethernia’s evidence →
Published result MitoImmune Immune-cell shifts are a human biological signal; reduced infections and longer survival remain separate questions.
Therapy / candidate Urolithin A
Company / institution Amazentis SA
Target / mechanism Mitochondrial quality control
Phase Not applicable
Population Healthy adults aged 45–70; enrollment 50
Primary endpoint T-cell population and mitochondrial activity changes over 28 days
Registry status Completed
Start date 2023-01-30
Expected / recorded primary completion 2024-03-31 (actual)
Last checked 2026-09-16
Registry last updated 2024-09-26 Started2023-01-30 Primary completion2024-03-31 (actual)
Registry record ↗ Read Ethernia’s evidence →
ETHERNIA